C aptopril and various other reduced sulfhydryl (SH) group-containing compounds, unlike non-SH-containing converting enzyme inhibitors, have antioxidant properties. 1 These properties include free radical scavenging 2, 3 and cardiovascular protective effects against ischemia and reperfusion injury, 4, 5 which have been presumed to depend on the presence of the reduced SH group. Certain evidence now suggests a relation of these SH-related effects to divalent cations such as Mg. First, Mg deficiency can directly cause coronary vasoconstriction, 6 myocardial ischemia, 7 and heart failure 8 ; it also reduces tolerance to ischemic damage in heart and erythrocytes and to reperfusion injury. 9 -11 A distinct, long-term Mg-deficient cardiomyopathy has been defined that can be reversed both by treatment with Mg and by the addition of SH-containing angiotensin-converting enzyme (ACE) inhibitors such as captopril but not by enalaprilat or by other non-SH converting enzyme-inhibiting compounds. 9, 12 In all of these circumstances, the mechanism of this thiol group-related protective action of captopril, although presumed to be secondary to free radical scavenging and the subsequent decrease in reactive oxygen species, has yet to be defined.
Second, our group has recently reported that reduced glutathione (GSH), a physiological SH group-containing antioxidant, directly increases intracellular total and free Mg levels in erythrocytes. 13 This was not true of oxidized glutathione, which is devoid of both a reduced SH group and any antioxidant activity. We wondered to what extent the protective effects against ischemic damage associated with other exogenous SH-containing compounds might be in part attributable to similar changes in cellular Mg content.
We therefore created a simple in vitro model of ischemic stress in human erythrocytes to investigate possible Mgrelated mechanisms by which captopril and other SH-group compounds might exert their protective effects. We used 31 P-nuclear magnetic resonance (NMR) spectroscopy to measure noninvasively intracellular free Mg (Mg i ), the highenergy phosphorylated metabolites ATP and 2,3-diphosphoglycerate (DPG), and the accumulation of inorganic phosphate (P i ) in erythrocytes before and during 6 hours of progressive oxygen deprivation and metabolite depletion in the presence and absence of captopril, other ACE inhibitors, and other SH reagents. The present data suggest that SH reagent-induced changes in Mg i levels may help to explain, in part, the protective effect of these compounds against ischemic damage, aside from other antioxidant, free radical-related effects they may exhibit.
Methods

Metabolite Depletion and Ischemic Stress Model
All volunteers gave informed consent in accordance with an institutional review committee-approved protocol at the Wayne State University Medical Center, Detroit, Mich. Twenty milliliters of heparinized blood was drawn between 9 AM and noon from unmedicated healthy volunteers (nϭ10;5 men, 6 women; mean age, 36.6Ϯ4.8 years; body mass index, 25.2Ϯ2.2 kg/m 2 ) after they fasted overnight. Ten milliliters of the blood was processed by 31 P-NMR techniques for analysis of the high-energy phosphate compounds 2,3-DPG and ATP. Basal measurements were taken, and then a stopper was placed atop the 12-mm NMR tube, thereby gradually decreasing the available oxygen and maximizing anaerobic fuel utilization; this incubation procedure was performed at 37°C in the presence and absence of 100 mol/L captopril (the dose at which the maximum effect on Mg i was observed; see Results). Measurements were repeated at hourly intervals for the next 6 hours. Previous NMR measurements had demonstrated the stability of basal values under aerobic conditions for 6 hours.
P-NMR Analysis of Mg i
The other 10 mL of blood from each patient sample was processed using 31 P-NMR techniques to measure erythrocyte Mg i levels before (basal, tϭ0 minutes) and 30, 60, and 120 minutes after the addition of various compounds: captopril (10 to 1000 mol/L), enalaprilat (10 to 100 mol/L), and other SH compounds, N-acetyl-L-cysteine (NAC, 300 mol/L), penicillamine (300 mol/L), and N-(2-mercaptopropionyl)-glycine (MPG, 300 mol/L). Doses of the other SH compounds tested were chosen to correspond to slightly more than the maximally effective Mg i -stimulating concentrations of captopril tested (see Results). The concentration range chosen for testing the effects of captopril was based on peak blood concentrations reported after oral administration of 10-and 100-mg doses of this drug to healthy male subjects. 14 The method for 31 P-NMR analysis of Mg i has been described in detail elsewhere. 15 In brief, 10 mL of heparinized blood was spun at 2000 rpm for 10 minutes, and the plasma was discarded. The remaining packed cell fraction was decanted into a 12-mm NMR tube, and 31 P-NMR spectra were recorded at 81 MHz at 37°C for 30 minutes on an XL200 spectrometer (Varian Associates Inc) in the Fourier transform mode with wide-band proton noise decoupling.
The Mg i concentration was determined according to the following equation:
where K d (MgATP) is the apparent dissociation constant for the reaction MgATPϭMg 2ϩ ϩATPϭ40 mol/L under physiological conditions of 37°C and pH 7.2; ⌽ϭ(ATP) free /(ATP) total , as determined from the chemical shift differences of the ␣-and ␤-phosphoryl group resonances of ATP in the 31 P-NMR spectrum. Because the above calculation is dependent on the steady-state equilibrium K d (MgATP) value, the lack of equilibrium associated with the ongoing changes in ATP levels during progressive oxygen depletion did not allow for a valid assessment of Mg i during ischemia in this model. Hence, the Mg i responses to all test substances reported here were measured only under basal conditions.
P-NMR Analysis of Erythrocyte Metabolites
31 P-NMR analysis was performed as described above. In the erythrocyte, the main phosphoryl resonances observed in the 31 P-NMR spectra are, sequentially, the 3-and 2-phosphate groups of 2,3-DPG and the ␥-, ␣-, and ␤-phosphate groups of ATP. In the metabolically intact erythrocyte, no distinct resonance associated with P i is observed, because the low levels present are obscured by the overlapping resonance of 2,3-DPG. However, with metabolite depletion associated with progressive oxygen depletion, a separate resonance peak associated with P i emerges (see Figure 1) . Hence, elevations of this peak, reciprocal decreases in the height and area of the 2,3-DPG and ATP peaks, and the ratio of the P i to 2,3-DPG (P i /2,3-DPG) peak heights were used as indexes of metabolite depletion and cell ischemia. 31 P-NMR spectra in erythrocytes before and after anaerobic incubation with and without captopril (100 mol/L).
Statistical Analysis
Data for time-dependent changes in Mg i and phosphorylated metabolite values before and after the in vitro addition of different compounds were analyzed for statistical significance using repeated measures ANOVA and subsequent post hoc t test (Super-Anova, Abacus Concept). Pearson's correlation coefficients were used to analyze the linear correlations between variables. Differences were considered to be statistically significant for PϽ0. 05 . All values are expressed as meanϮSEM.
Results
With the onset of progressive oxygen depletion, which maximized anaerobic glucose use, a progressive fall in 2,3-DPG and ATP levels occurred over 4 to 6 hours, associated with the occurrence of and progressive rise in a distinct phosphoryl resonance peak due to P i accumulation (Figures 1 and 2 ). These observations were quantitatively combined as the P i /2,3-DPG ratio, which served as an index of metabolite depletion and failing cell viability. Under the same circumstances, incubation with captopril significantly retarded the rise in P i compared with control and significantly reduced the P i /2,3-DPG at 4 and 6 hours ( Figure 2 ). Specifically, in control samples, P i /2,3-DPG rose from 0.02Ϯ0.02 (tϭ0, basal) to 0.59Ϯ0.17 (tϭ4 hours), and to 1.39Ϯ0.33 at 6 hours of incubation. In contrast, in samples incubated with 100 mol/L captopril, the rise in P i /2,3-DPG was significantly blunted, from 0.02Ϯ0.02 (basal) to 0.40Ϯ0.10 (tϭ4 hours) to 0.93Ϯ0.20 (tϭ6 hours) (PϽ0.008 and PϽ0.025 at tϭ4 and 6 hours, respectively, versus controls; Figure 2) .
Under basal circumstances, captopril significantly elevated Mg i levels (Table; Figures 3a and 3b) ; enalaprilat did not. Specifically, captopril increased erythrocyte Mg i in a timeand dose-dependent fashion over the course of 120 minutes and at doses of 10 to 1000 mol/L. These Mg i effects were maintained for 6 hours, the time during which progressive oxygen depletion was studied (see below). Peak Mg i effects were observed at 60 minutes and at a concentration of 100 mol/L. At 60 minutes at different captopril doses, Mg i levels were 174.5Ϯ5. (Figure 1 ). In contrast, incubation with enalaprilat (10 to 100 mol/L) for 60 minutes did not significantly alter Mg i content (Table) .
However (Table) .
Altogether, a significant positive relationship was observed between the captopril-induced rise in Mg i levels and its protective effects on metabolite depletion: the greater the captopril-induced rise in Mg i , the greater the protective effect (rϭ0.823, PϽ0.01) (Figure 4) . A further interaction between the Mg i status of the cell and the effect of captopril was noted when the captopril-induced change in Mg i was compared with basal Mg i levels. The higher the basal Mg i level, the greater the Mg i responsiveness (rϭ0.799, PϽ0.01), and, Figure 2 . Effects of captopril on ischemic stress in erythrocytes. Pi/2,3-DPG measured with 31 P-NMR techniques was used as an index of cell ischemic damage and metabolite depletion in erythrocytes during 6 hours of progressive anaerobic incubation with and without captopril (100 mol/L). *PϽ0.05 and **PϽ0.01 vs tϭ60 minutes. hence, the higher the basal Mg i , the greater the protective effect exerted by captopril (rϭ0.751, PϽ0.015).
Effects of Enalaprilat and SH Compounds on Mg i Levels
Compound Basal, mol/L Maximal Effect, mol/L
Discussion
Our group has focused on the role of altered cellular ion metabolism in mediating final common pathways of vascular diseases associated with hypertension, insulin resistance, diabetes mellitus, and aging. 16 -18 Current interest in the protective role of antioxidant compounds in cardiovascular disease recently led us to investigate the effects of the endogenous SH-containing antioxidant glutathione (reduced form, GSH) on Mg, in which reduced, but not oxidized glutathione stimulated Mg i content in human erythrocytes. 13 In the present report, we used a simple in vitro model of ischemic stress in human erythrocytes to investigate the protective effects of exogenous SH compounds and the extent to which their protective effects could be linked to concomitant effects on Mg i levels.
With this red blood cell ischemic model, our present data show the following: (1) that both 2,3-DPG and ATP levels fall, whereas a separate P i peak gradually emerges, and all of the above is reflected by the measurement of increased P i /2,3-DPG over time; (2) that captopril and other SH compounds, such as NAC, penicillamine, and MPG all can enhance basal Mg i levels in erythrocytes, although the non-SH-containing enalaprilat cannot; (3) that captopril blunts ischemia-induced metabolite depletion, as indicated by the delayed rise in P i , and P i /2,3-DPG; and (4) that the protective effect of captopril on the above responses to ischemic stress was directly related to its effects on Mg i : the higher the captopril-induced rise in Mg i , the lower the P i /2,3-DPG, and thus the greater the protective effect (Figure 4) . Furthermore, (5) the cellular Mg i response to captopril is itself dependent on basal Mg i levels: the greater the Mg i , the more captopril increases Mg i and the more it protects against ischemic stress. Altogether, these data suggest (1) that oxygen deprivation of human erythrocytes in vitro provides a reasonable model system to test the protective effects of various agents against the metabolite depletion accompanying ischemic stress and (2) that the mechanism(s) by which SH compounds exert their protective effects may not be limited to the welldemonstrated actions of these compounds on free radical scavenging, but also may include their action to elevate Mg i levels.
Our present results are also consistent with previous observations in the literature that emphasize the significance of Mg deficits in cardiovascular ischemia. Increased oxygen free radical production, which may contribute to the pathophysiology of several human diseases, 19 is associated with low intracellular Mg concentrations, 20 and growing evidence links oxidative injury to Mg deficiency. 21, 22 Not only does Mg deficiency sensitize the myocardium to ischemic injury, 9 but preexisting Mg deficiency is associated with myocardial free radicals such as ferrylmyoglobin 23 and predisposes postischemic hearts to enhanced oxidative damage and functional loss, 24 protection against which is afforded by various antioxidant compounds. 21 More generally, chronic hypomagnesemia 25 and conditions commonly associated with Mg deficiency, such as diabetes mellitus 26 and aging, 20 are all associated with an increase in free radical formation with subsequent damage to cellular processes. Indeed, Mg may itself possess antioxidant properties and scavenge oxygen radicals, possibly by affecting the rate of spontaneous dismutation of the superoxide ion. 22 In dogs, it has been recently demonstrated that Mg infusions significantly attenuate the enhanced free radical formation after a 20-minute occlusion of the left anterior descending coronary artery followed by reperfusion. 27 While both the carbonyl and thiol groups of captopril are essential for its activity as an ACE inhibitor, the antioxidant effects of captopril seem to depend on the SH moiety alone. Thus, SH compounds such as MPG, which exhibits no ACE-inhibiting activity, also protect hearts against myocardial ischemia and reperfusion in a concentrationdependent manner. Conversely, non-SH-containing ACE inhibitors such as enalaprilat are not protective. 28 Similarly, SH-containing ACE inhibitors also protect endothelial cells in vitro against exogenously generated free radicals, 3 and captopril, epicaptopril (a stereoisomer of captopril), and zofenopril all significantly protected male hamsters from cardiomyopathy due to Mg deficiency, whereas enalaprilat afforded only a slight (nonsignificant) protection. 12 Captopril and zofenopril have also been found to attenuate postischemic contractile dysfunction of the viable but stunned myocardium during the early hours after relief from ischemia, whereas there is no consensus on the effects of other ACE inhibitors. 29 In erythrocytes, captopril was protective against various oxidant stresses: hemolysis caused by 2,2Ј-azobis and hypochlorite, lipid peroxidation of erythrocyte membranes caused by tertbutyl-hydroperoxide (tBOOH) and hypochlorite, inactivation of erythrocyte membrane ATPases caused by tBOOH, and oxidation of hemoglobin caused by AAPH and tBOOH. Interestingly, increased membrane lipid peroxidation itself, as well as alterations of fatty acid composition and lipid-derived messengers, result from low-Mg environments. 30, 31 In all of these systems, the antioxidant effects observed have been related to the SH group; enalapril was either not protective or even increased the damage. 32 Thus, although both Mg and SH compounds possess antioxidant properties, this is the first report in which a relation has been suggested between Mg itself and captopril-induced protection against metabolite depletion after ischemic stress. Although the mechanism of this Mg i -SH compound linkage remains undefined, it seems reasonable to suggest that the ability of endogenous glutathione to increase erythrocyte Mg i levels 13 is being mimicked by the various exogenous SH-containing compounds tested here. Thus, GSH depends on an adequate supply of NADPH, which is normally derived from oxidative glucose metabolism in the erythrocyte through the pentose phosphate shunt pathway. Because the turnover of GSH is high, progressive oxygen deprivation would, by decreasing renewable NADPH stores, reduce endogenous GSH content. Furthermore, by placing an increased energy reliance on anaerobic glycolysis, ischemia makes the nonrenewable substrate availability in the test tube rate limiting, thereby increasing high-energy metabolite degradation. Under these conditions, exogenous SH compounds, by functioning as "substitute" GSH molecules, would provide the same direct antioxidant and Mg i -stimulating actions as would GSH itself, which would result in protection against the accelerated metabolite depletion, as we observed here.
Certain caveats that may limit the interpretation of the data should be considered. First, we did not perform complete dose-response curves for the noncaptopril compounds studied here. We thus cannot compare them with regard to their relative potency in stimulating Mg i levels in relation to the ability to protect against the ischemic changes induced in our model, which were not studied. Second, we did not measure cytosolic free calcium levels in this study, changes to which may mediate some of the cellular effects of magnesium deficiency, and which, consistent with studies in the literature, 30, 33, 34 are directly regulated by both extracellular and intracellular Mg content. Third, although we believe certain insights may be gained from the use of this in vitro red blood cell-based ischemic stress model, the clinical relevance of our findings remain uncertain. Thus, these data clearly need to be substantiated and their implications tested in other model systems and ultimately in clinical disease states that involve direct insults to cardiac, brain, and/or peripheral vascular tissues.
These caveats notwithstanding, however, the present results demonstrate the direct in vitro actions of captopril to enhance Mg i content and to retard high-energy phosphate metabolite depletion after progressive oxygen deprivation, actions that appear to be related. Our data are thus consistent with a role of Mg i , at least in part, in the protective effect of captopril against ischemic injury. The utility of this simple model of red blood cell ischemic stress and further considerations concerning the mechanisms underlying this Mg ionicantioxidant relationship will be the subject of future experiments.
